Oxidation pathway and exacerbations in COPD: the role of NAC. (Q38633304)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26567752%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Oxidation pathway and exacerbations in COPD: the role of NAC (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26567752%20AND%20SRC:MED&resulttype=core&format=json

chronic obstructive pulmonary disease

29 February 2020

main subject

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26567752%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Maria Gabriella Matera

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26567752%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Mario Cazzola

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26567752%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

15 December 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26567752%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Respiratory Medicine

29 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26567752%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26567752%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26567752%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

89-97

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26567752%20AND%20SRC:MED&resulttype=core&format=json

Antioxidant pharmacological therapies for COPD.

29 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Oxidants, oxidative stress and the biology of ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

COPD: balancing oxidants and antioxidants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Oxidative stress in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Oxidative stress and free radicals in COPD--implications and relevance for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Oxidative stress and airway inflammation in severe exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

The systemic availability of oral glutathione

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Gamma-glutamyl transpeptidase in glutathione biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

The effect of cysteine oxidation on isolated hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Molecular mechanisms of N-acetylcysteine actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Kinetic studies of covalent binding between N-acetyl-L-cysteine and human serum albumin through a mixed-disulfide using an N-methylpyridinium polymer-based column

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Identification of a mechanism by which the methylmercury antidotes N-acetylcysteine and dimercaptopropanesulfonate enhance urinary metal excretion: transport by the renal organic anion transporter-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Long-term oral n-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Inhaled muscarinic antagonists for COPD--does an anti-inflammatory mechanism really play a role?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Priming of beta-2 agonist and antimuscarinic induced physiological responses induced by 1200mg/day NAC in moderate to severe COPD patients: A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Defining phenotypes in COPD: an aid to personalized healthcare.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Outcomes for COPD pharmacological trials: from lung function to biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2016.1121105

10.1586/17476348.2016.1121105

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26567752%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference